Key facts
- It has raised $5.8M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Tech Incubator Program for Startup, KDB Capital, DAYLI Partners, Magna Investment (Seoul), Innopolis Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Gencellmed
- ·The full record, as it builds
Funding rounds
No funding rounds for Gencellmed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gencellmed
Developer of an anti-cancer drug treatment platform intended to develop next-generation immune-enhancing anti-cancer herpes virus (oHSV-1) drugs. The company specializes in developing the next-generation new drug against herpesviruses (oHSV-1) with dual action to stimulate the infectious power of cancer cells and the body's immune response, providing medical professionals with drugs to cure cancer.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 9
- Website
- gencellmed.com/
- Ownership
- Privately Held (backing)
Gencellmed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gencellmed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gencellmed in its N-PORT filings yet. We sweep new filings monthly.